44 results on '"Rampurwala, Murtuza"'
Search Results
2. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
3. Optimal breast cancer risk reduction policies tailored to personal risk level
4. PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1).
5. Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel
6. Abstract CT161: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the non-epithelial ovarian tumor cohort
7. Data from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
8. Supplmentary Figures from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
9. Supplementary Tables. from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
10. Appendix.pdf from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
11. Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer
12. Recurrent Acute Pancreatitis and Persistent Hyperamylasemia as a Presentation of Pancreatic Osteoclastic Giant Cell Tumor: An Unusual Presentation of a Rare Tumor
13. Selective Left Anterior Descending Shunting Provides Effective Off-pump Myocardial Protection
14. A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
15. Non-Functioning Pancreatic Neuroendocrine Tumors—A Case Report and Review of Literature
16. Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an individualized treatment strategy for metastatic disease
17. Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): Secondary and final primary efficacy analyses.
18. Evaluation of the Association of Perioperative UGT1A1 Genotype–Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma
19. Personalized ANtibodies for GastroEsophageal Adenocarcinoma (PANGEA): Primary efficacy analysis of the phase II platform trial (NCT02213289).
20. Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
21. Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing ‘gFOLFIRINOX’ for gastroesophageal adenocarcinoma (GEA).
22. Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II precision medicine trial (NCT02213289).
23. Pharmacodynamic phase I study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel.
24. Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer
25. Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
26. A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.
27. Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.
28. Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)
29. Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel.
30. Abstract 2638: Novel synergy of radiosensitizer prodrug IPdR with Aurora kinase inhibitors in triple-negative breast cancer
31. Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.
32. Update on Adjuvant Chemotherapy for Early Breast Cancer
33. PO84 VISUALIZING TREATMENT AND OUTCOMES IN METASTATIC BREAST CANCER
34. Role of the Androgen Receptor in Triple-Negative Breast Cancer.
35. Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib
36. Off-pump coronary artery bypass and avoidance of hypothermic cardiac arrest improves early left ventricular function in patients with systolic dysfunction
37. Delayed Hepatic Metastasis From a Benign Fibroblastic Meningioma Thirty-One Years After Surgical Resection of the Intracranial Tumor
38. Non-Functioning Pancreatic Neuroendocrine Tumors—A Case Report and Review of Literature
39. Rituximab Induced Serum Sickness Masquerading as Septic Shock
40. Visualization and Quantification of Intraperitoneal Tumors by In Vivo Computed Tomography Using Negative Contrast Enhancement Strategy in a Mouse Model of Ovarian Cancer
41. Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib.
42. Primary gastric combined adeno-small cell neuroendocrine carcinoma.
43. SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer.
44. Update on adjuvant chemotherapy for early breast cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.